Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.77 |
| ▸ | DDB1 | Q16531 | 6/20 | 0.77 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.53 |
| ▸ | PYGL | P06737 | 2/20 | 0.49 |
| ▸ | PYGM | P11217 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31316573 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3PYGLPYGM | |
| SCHEMBL23355793 | 1.00 | CRBN (0.77) | CRBNDDB1IKZF3PYGLPYGM | |
| SCHEMBL31316584 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3 | |
| SCHEMBL23355802 | 0.87 | CRBN (1.00) | CRBNDDB1IKZF3 | |
| SCHEMBL9366340 | 0.83 | CRBN (0.73) | CRBNDDB1IKZF3PYGLPYGM | |
| SCHEMBL23355824 | 0.80 | KMT2A (0.55) | CRBNDDB1POLB | |
| SCHEMBL23355823 | 0.80 | KMT2A (0.55) | CRBNDDB1POLB | |
| SCHEMBL30080373 | 0.76 | MEN1 (0.50) | CRBNDDB1PYGLPYGMSMN1; SMN2 | |
| SCHEMBL28604054 | 0.75 | MEN1 (0.52) | CRBNDDB1PYGLPYGMSMN1; SMN2 | |
| SCHEMBL3646204 | 0.73 | SMYD3 (0.61) | CRBNDDB1SMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| CN-112512589-A | Dimeric immunomodulatory compounds against CEREBLON-based mechanisms | H·李·莫菲特癌症中心研究有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885DDB1 1404/4885IKZF3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.